ProQR Therapeutics
PRQR
55 hedge funds and large institutions have $215M invested in ProQR Therapeutics in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 18 reducing their positions, and 8 closing their positions.
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
2% less funds holding
Funds holding: 56 → 55 (-1)
4.18% less ownership
Funds ownership: 64.97% → 60.79% (-4.2%)
17% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 18
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
37% less capital invested
Capital invested by funds: $340M → $215M (-$125M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$5.51M |
| 2 |
KA
Kerrisdale Advisers
Miami,
Florida
|
+$4.74M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.3M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.29M |
| 5 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$3.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$10M |
| 2 |
O
OrbiMed
New York
|
-$7.07M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
-$4.02M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.63M |
| 5 |
Goldman Sachs
New York
|
-$2.21M |
PRQR Hedge Fund Activity: Q2 2019 in Review
55 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q2 2019, worth a combined $215M — down 37% from $340M a quarter earlier.
Fund positioning in PRQR was balanced in Q2 2019: 8 funds opened new positions, 8 closed out, 15 added to existing stakes and 18 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $5.51M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $10M sold.
- 55 institutional investors held ProQR Therapeutics (PRQR) as of Q2 2019, down from 56 in Q1 2019.
- Funds reported $215M of ProQR Therapeutics stock for Q2 2019, down 37% quarter-over-quarter.
- 8 funds opened new ProQR Therapeutics positions in Q2 2019 and 8 closed out, a net change of 0 holders.
- The largest ProQR Therapeutics buyer in Q2 2019 was UBS Group, an estimated $5.51M added.
- The largest ProQR Therapeutics seller in Q2 2019 was Perceptive Advisors, an estimated $10M sold.
Based on aggregated 13F filings for Q2 2019.